Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.3K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.3K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

11.2K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
11.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Hematopoiesis01:21

Hematopoiesis

9.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.

Blood·2026
Same author

Gram-negative blood-stream infections and emerging antimicrobial resistance in children with acute myeloid leukemia during induction chemotherapy at Children's Cancer Hospital Egypt 57357.

Frontiers in oncology·2026
Same author

Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment.

Transplantation and cellular therapy·2026
Same author

Impact of Adolescent and Young Adult Cancer Expertise in Oncologists on AYA Outcomes in Hodgkin Lymphoma: A Population-Based Study in Ontario, Canada.

Cancer medicine·2026
Same author

Treatment and Outcomes of Children and Adults With Rhabdomyosarcoma in Rwanda.

Pediatric blood & cancer·2026
Same author

Preemptive Versus Empirical Antifungal Therapy for High-Risk, Febrile, Neutropenic Solid Tumor Patients in an LMIC Setting.

Pediatric blood & cancer·2025
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Mar 23, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

1.0K

Global Approach to Hematologic Malignancies.

Leslie Lehmann1, Alaa El-Haddad2, Ronald D Barr3

  • 1Pediatric Stem Cell Transplant, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.

Hematology/Oncology Clinics of North America
|April 5, 2016
PubMed
Summary
This summary is machine-generated.

Treating childhood blood cancers in resource-poor areas is challenging but essential. Tailored therapies and research are key to improving outcomes for acute lymphoblastic leukemia and lymphomas.

Keywords:
GlobalHematologic malignanciesLeukemiaLow- and middle-income countries (LMIC)LymphomaPediatric

More Related Videos

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

642
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K

Related Experiment Videos

Last Updated: Mar 23, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

1.0K
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

642
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K

Area of Science:

  • Pediatric Hematology Oncology
  • Global Health
  • Cancer Treatment Disparities

Background:

  • Childhood hematologic malignancies necessitate multidisciplinary care and robust infrastructure.
  • Resource-poor settings face significant challenges in establishing adequate healthcare structures for these conditions.
  • Acute lymphoblastic leukemia (ALL) and lymphomas are prevalent in low- and middle-income countries (LMICs), demanding resource-intensive treatments.

Purpose of the Study:

  • To highlight the challenges and essential components for treating childhood hematologic malignancies in resource-poor settings.
  • To emphasize the need for region- and disease-specific therapeutic strategies.
  • To underscore the importance of research initiatives and palliative care.

Main Methods:

  • Review of current challenges in pediatric hematologic malignancy treatment in LMICs.
  • Analysis of common hematologic malignancies and their treatment requirements.
  • Discussion of cost-effectiveness and outcome disparities.

Main Results:

  • Outcomes for childhood hematologic malignancies are poorer in LMICs compared to high-income countries.
  • Effective treatments like imatinib exist for conditions such as chronic myeloid leukemia.
  • Tailored therapy, reduced treatment burden, and palliative care are crucial.

Conclusions:

  • Developing effective treatment strategies for childhood blood cancers in resource-limited environments requires tailored approaches and research.
  • Addressing disparities in care and implementing robust palliative programs are vital for improving survival rates.
  • Optimizing treatment protocols and infrastructure is essential for equitable pediatric cancer care globally.